Treatment of short bowel syndrome patients with colon-in-continuity
Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
1. A method of treating an adult human patient having short bowel syndrome without inflammatory bowel disease, who receives an amount of parenteral nutrition each week, and who presents with colon-in-continuity with remnant small intestine, said method comprising administering [Gly2]hGLP-2 to said patient using a dosing regimen effective to reduce or eliminate said weekly amount of parenteral nutrition received by said patient.
2. The method as defined in claim 1 , wherein the [Gly2]hGLP-2 is administered at a daily dose of from 5 to 500 μg/kg.
3. The method as defined in claim 2 , wherein the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 μg/kg.
4. The method as defined in claim 1 , wherein the [Gly2]hGLP-2 is administered by subcutaneous injection.
5. The method as defined in claim 4 , wherein the subcutaneous injection is into the abdomen, thigh, or arm.
6. A method of treating an adult human patient having short bowel syndrome without inflammatory bowel disease, who receives an amount of parenteral nutrition each week, and who presents with colon-in-continuity with remnant small intestine, said method comprising administering [Gly2]hGLP-2 to said patient using a dosing regimen effective to increase wet weight absorption compared to a baseline wet weight absorption by said patient.
7. The method as defined in claim 6 , wherein the [Gly2]hGLP-2 is administered at a daily dose of from 5 to 500 μg/kg.
8. The method as defined in claim 7 , wherein the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 μg/kg.
9. The method as defined in claim 6 , wherein the [Gly2]hGLP-2 is administered by subcutaneous injection.
10. The method as defined in claim 9 , wherein the subcutaneous injection is into the abdomen, thigh, or arm.
11. The method as defined in claim 1 , wherein said regimen comprises administration of the [Gly2]hGLP-2 over a period of at least 21 days.
12. The method as defined in claim 6 , wherein said regimen comprises administration of the [Gly2]hGLP-2 over a period of at least 21 days.
13. The method as defined in claim 1 , wherein the parenteral nutrition is reduced by volume or frequency of administration.
14. The method as defined in claim 1 , wherein said patient is an adult and the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 μg/kg by subcutaneous injection.
15. The method as defined in claim 6 , wherein said patient is an adult and the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 μg/kg by subcutaneous injection.